11月4日，康希诺生物盘中上涨5.06%，报25.74港元，成交额6438.74万港元。
消息面上，公司此前披露三季报，前三季度实现营收8.82亿元，同比增长27.40%；归母净利润1629.13万元，同比增长12.82%，为股价提供基本面支撑。与此同时，当日港股生物科技板块整体走强，百济神州、康方生物、信达生物等涨幅居前，带动相关个股活跃。
此外，公司最新月报显示10月总股本维持247,043,801股不变，报告期内未新增发行、回购或注销股份，公众持股量亦持续符合上市规则。
康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.